Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marija Balic

Showing results (71-80 of 121) with videos related to

Pageof 13
Sort By:
Cytometry. Part B, Clinical Cytometry|September 6, 2005
Comparison of two methods for enumerating circulating tumor cells in carcinoma patientsMarija Balic, Nadia Dandachi, Günter Hofmann, et al.
Cancers|June 2, 2021
Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment IntensityChristoph Suppan, Florian Posch, Hannah Deborah Mueller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
Prediction of Distant Recurrence Using EndoPredict Among Women with ER<sup>+</sup>, HER2<sup>-</sup> Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy OnlyMartin Filipits, Peter Dubsky, Margaretha Rudas, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trialChristian F Singer, Franz Koenig, Stephanie Kacerovsky-Strobl, et al.
NPJ Precision Oncology|November 9, 2024
Immune infiltration correlates with transcriptomic subtypes in primary estrogen receptor positive invasive lobular breast cancerFangyuan Chen, Sayali Onkar, Jian Zou, et al.
Molecular Oncology|June 13, 2024
Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progressionEva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, et al.
British Journal of Cancer|November 10, 2021
Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patientsChristoph Suppan, Ricarda Graf, Stephan Jahn, et al.
BMC Cancer|November 8, 2018
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, et al.
American Journal of Clinical Pathology|February 26, 2026
Magee Equation 3 demonstrates predictive and prognostic value for neoadjuvant chemotherapy outcomes in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancerJacob A Jerome, Rachel Vanderschelden, Beth Z Clark, et al.
Medrxiv : the Preprint Server for Health Sciences|September 15, 2025
Interim Analysis of Dose-Escalated Preoperative Breast Irradiation: A Phase Ib studyRavi Patel, Emilia Diego, Hayeon Kim, et al.
Pageof 13

Showing results (71-80 of 121) with videos related to

Sort By:
Pageof 13
Cytometry. Part B, Clinical Cytometry|September 6, 2005
Comparison of two methods for enumerating circulating tumor cells in carcinoma patientsMarija Balic, Nadia Dandachi, Günter Hofmann, et al.
Cancers|June 2, 2021
Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment IntensityChristoph Suppan, Florian Posch, Hannah Deborah Mueller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
Prediction of Distant Recurrence Using EndoPredict Among Women with ER<sup>+</sup>, HER2<sup>-</sup> Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy OnlyMartin Filipits, Peter Dubsky, Margaretha Rudas, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trialChristian F Singer, Franz Koenig, Stephanie Kacerovsky-Strobl, et al.
NPJ Precision Oncology|November 9, 2024
Immune infiltration correlates with transcriptomic subtypes in primary estrogen receptor positive invasive lobular breast cancerFangyuan Chen, Sayali Onkar, Jian Zou, et al.
Molecular Oncology|June 13, 2024
Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progressionEva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, et al.
British Journal of Cancer|November 10, 2021
Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patientsChristoph Suppan, Ricarda Graf, Stephan Jahn, et al.
BMC Cancer|November 8, 2018
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, et al.
American Journal of Clinical Pathology|February 26, 2026
Magee Equation 3 demonstrates predictive and prognostic value for neoadjuvant chemotherapy outcomes in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancerJacob A Jerome, Rachel Vanderschelden, Beth Z Clark, et al.
Medrxiv : the Preprint Server for Health Sciences|September 15, 2025
Interim Analysis of Dose-Escalated Preoperative Breast Irradiation: A Phase Ib studyRavi Patel, Emilia Diego, Hayeon Kim, et al.
Pageof 13